Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?

por Nobile, B., Durand, M., Courtet, P., Van de Perre, P., Nagot, N., Molès, J.P., Olié, E.
Publicado 2020

P07-11 LB. Impact of highly active antiretroviral therapy on cell-free and cell-associated HIV-1 in cervicovaginal secretions and blood

por Rubbo, P, Tuaillon, E, Nagot, N, Bolloré, K, Valéa, D, Vendrell, J, Konaté, I, Ouédraogo, A, Huet, C, Foulongne, V, Perre, P Van de
Publicado 2009

Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso

por Didelot-Rousseau, M-N, Nagot, N, Costes-Martineau, V, Vallès, X, Ouedraogo, A, Konate, I, Weiss, H A, Van de Perre, P, Mayaud, P, Segondy, M
Publicado 2006

P15-25. Preparation for HIV vaccine trials in Africa: barriers and facilitators for the establishment of a community advisory board in Burkina Faso

por Berthe, A, Meda, N, Traoré, IT, Some, J, Salouka, S, Sanou, L, Some, F, Rouamba, J, Ouedraogo, D, M'Boutiki, G, Mayaud, P, Nagot, N, perre, P Van de
Publicado 2009

Devenir des patients hospitalisés en soins critiques pour infection à SARS-COV2 : évaluation standardisée des séquelles à 6–9 mois

por Berger, M., Daubin, D., Charriot, J., Klouche, K., Le Moing, V., Arnaud, B., Morquin, D., Jaussent, A., Taourel, P., Hayot, M., Nagot, N., Fesler, P., Roubille, C.
Publicado 2022